中國再保險(01508.HK):中再壽險附屬中再香港獲授權可在香港經營保險業務
格隆匯12月17日丨中國再保險(01508.HK)公佈,公司附屬公司中國人壽再保險有限責任公司(中再壽險)全資附屬公司中國再保險(香港)股份有限公司(中再香港)於近日獲香港保監局授權在香港或從香港經營保險業務。該公司註冊資本為港幣20億元,註冊地在香港,其主要業務為人身再保險業務。
公告顯示,中再壽險於香港設立附屬公司,是公司推進國際化戰略佈局的重要舉措。憑藉香港的人才、技術和離岸人民幣結算優勢,國際市場先進的業務模式和管理經驗,中再香港的成立將提升公司國際再保險業務的集中化和專業化管理水平,拓展包括香港和新興亞太地區在內的新業務增長點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.